<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04376827</url>
  </required_header>
  <id_info>
    <org_study_id>CR108766</org_study_id>
    <secondary_id>2018-003155-38</secondary_id>
    <secondary_id>CNTO1959LUN2001</secondary_id>
    <nct_id>NCT04376827</nct_id>
  </id_info>
  <brief_title>A Study of Guselkumab in Participants With Active Lupus Nephritis</brief_title>
  <acronym>ORCHID-LN</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects With Active Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of guselkumab in participants with
      active lupus nephritis (LN).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Guselkumab is a monoclonal antibody (mAb) that binds to human interleukin (IL)-23 with high
      affinity and blocks binding of extracellular IL-23 to cell surface IL-23 receptor, inhibiting
      IL 23 specific intracellular signaling and subsequent activation and cytokine production. It
      is used in treatment of psoriatic arthritis, generalized pustular psoriasis, erythrodermic
      psoriasis. Lupus is a heterogeneous autoimmune disease with lesions confined to skin
      (cutaneous lupus erythematosus [CLE]) to others that involve 1 or more vital internal organs
      (systemic lupus erythematosus [SLE]). Renal involvement due to SLE is termed lupus nephritis
      (LN). There is a high unmet need for new treatment options in LN that are safe and effective,
      especially new therapies that can provide improved long-term efficacy over currently
      available therapies. This study will evaluate safety and efficacy of guselkumab added to
      standard-of-care compared to placebo added to standard-of-care. Total duration of study is up
      to 68 weeks: a less than or equal to 8 week screening period, a 48 week double-blind
      treatment period, a 12 week safety follow-up period after last dose. Hypothesis of this study
      is that guselkumab plus standard-of-care is superior to placebo plus standard-of-care in
      participants with active LN as measured by the proportion of participants inducing at least a
      50 percentage reduction of proteinuria with protocol specified steroid tapering regimen at
      Week 24. Safety assessments include Adverse event (AEs), clinical laboratory tests
      (hematology and chemistry), systolic and diastolic blood pressures over time, monitoring for
      hypersensitivity reactions, AEs temporally associated with infusion, injection-site
      reactions, suicidality assessment, and early detection of active tuberculosis (TB).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 27, 2020</start_date>
  <completion_date type="Anticipated">March 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 5, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving at Least 50 Percentage (%) Decrease in Proteinuria</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Percentage of participants achieving at least 50% decrease in proteinuria from baseline at Week 24 will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Complete Renal Response (CRR)</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants achieving complete renal response will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Sustained Reduction in Steroid Dose &lt;=10 milligram (mg)/day of Prednisone or Equivalent</measure>
    <time_frame>Week 16 to Week 24</time_frame>
    <description>Percentage of participants achieving a sustained reduction in steroid dose less than or equal to (&lt;=) 10 mg/day of prednisone or equivalent will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving at Least 50% Decrease in Proteinuria From Baseline at Week 52</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Percentage of participants achieving at least 50% decrease in proteinuria from baseline at Week 52 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Complete Renal Response</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of participants achieving CRR will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Urine Protein to Creatinine Ratio (UPCR) &lt;0.5 mg/mg</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants with UPCR &lt;0.5 mg/mg will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with UPCR &lt; 0.75 mg/mg</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants with UPCR less than (&lt;) 0.75 milligram/milligram (mg/mg) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achievement of Complete Renal Response</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Time to achievement of CRR will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (TF)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Time to treatment failure will be reported. Treatment failure criteria include: initiation or increased use of a glucocorticoid or other immunosuppressive agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Event (AE) serious adverse events (SAEs), reasonably related AEs, as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Number of Participants with Adverse Event (AE) serious adverse events (SAEs), reasonably related AEs will be assessed. AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product does not necessarily have a causal relationship with the treatment. Therefore, it can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product. A serious adverse event is any untoward medical occurrence that at any dose results in death, is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is a suspected transmission of any infectious agent via a medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with AE Leading to Discontinuation of Study Intervention</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Number of participants with AE leading to discontinuation of study intervention will be reported. AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product does not necessarily have a causal relationship with the treatment. Therefore, it can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Infections</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Number of participants with infections will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Infections</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Number of Participants with serious infections will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Infections Requiring Oral or Parenteral Antimicrobial Treatment</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Number of participants with infections requiring oral or parenteral antimicrobial treatment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants With AEs temporally associated with an infusion, and injection-site reactions</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Number of participants with AEs temporally associated with an infusion, and injection-site reactions will be reported. An injection-site reaction is any adverse reaction at a SC study intervention injection-site. AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product does not necessarily have a causal relationship with the treatment. Therefore, it can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Laboratory Parameters</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Change from baseline in laboratory parameters (hematology and chemistry) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Maximum Common Terminology Criteria for Adverse Events (CTCAE) toxicity grade Laboratory Values</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Number of participants with maximum CTCAE toxicity grade laboratory values will be reported. Grade refers to the severity of the AE as follows: Grade 1- Mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2- Moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental Activities of Daily Living (ADL); Grade 3- Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care ADL; Grade 4- Life-threatening consequences, urgent intervention indicated; Grade 5- Death related to AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and Diastolic Blood Pressures Over Time</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Systolic and diastolic blood pressures over time will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Guselkumab</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Serum Concentration of guselkumab will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-Guselkumab Antibodies</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Number of participants with anti-drug antibodies to guselkumab will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Guselkumab+Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive guselkumab Dose 1 intravenously (IV) at Weeks 0, 4 and 8 and guselkumab Dose 2 subcutaneous (SC) every 4 weeks (q4w) from Week 12 through Week 48 along with standard-of-care treatment of mycophenolate mofetil (MMF)/mycophenolic acid (MPA) and glucocorticoids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+Standard of Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo IV at Weeks 0, 4 and 8 and placebo SC q4w from Week 12 through Week 48 along with standard-of-care treatment of MMF/MPA and glucocorticoids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guselkumab Dose 1</intervention_name>
    <description>Participants will receive guselkumab Dose 1 via IV administration.</description>
    <arm_group_label>Guselkumab+Standard of Care</arm_group_label>
    <other_name>CNTO 1959</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo IV at Weeks 0, 4 and 8 (that is, 3 IV doses) and placebo SC q4w from Week 12 through Week 48.</description>
    <arm_group_label>Placebo+Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guselkumab Dose 2</intervention_name>
    <description>Participants will receive guselkumab Dose 2 via SC route.</description>
    <arm_group_label>Guselkumab+Standard of Care</arm_group_label>
    <other_name>CNTO1959</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard-of-care treatment</intervention_name>
    <description>Participants will receive standard of care treatment including MMF/MPA and glucocorticoids from Week 12 through Week 48.</description>
    <arm_group_label>Guselkumab+Standard of Care</arm_group_label>
    <arm_group_label>Placebo+Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently receiving prednisone equivalent dose of 1 milligram per kilogram per day
             (mg/kg/day) or less than or equal to (&lt;=) 60 mg/day, whichever is lower, or less. Must
             be receiving prednisone equivalent of 10 mg/day or more at screening and
             randomization. Treated for greater than or equal to (&gt;=) 6 weeks with stable dosing
             &gt;=2 weeks before randomization

          -  If receiving angiotensin-converting enzyme (ACE) inhibitor/angiotensin II receptor
             blockers (ARB), a stable dose for at least 2 weeks prior to randomization

          -  Positive antinuclear antibody (ANA; &gt;= 1:80 titer by central laboratory test) or
             positive anti-double-stranded deoxyribonucleic acid (dsDNA) test results at screening

          -  Kidney biopsy documentation of International Society of Nephrology (ISN)/Renal
             Pathology Society (RPS) proliferative nephritis: Class III-IV within the last 6 months
             prior to screening or performed during screening

          -  Urine Protein to Creatinine Ratio (UPCR) &gt;= 1.0 milligram/milligram (mg/mg) assessed
             on 2 first morning urine void specimens during screening. These 2 specimens do not
             need to be on consecutive days, however, 2 samples must be tested with UPCR &gt;= 1.0
             mg/mg in a row. The UPCR requirement must be met after at least 8 weeks of
             mycophenolate mofetil (MMF)/mycophenolic acid (MPA) treatment, and after stable
             glucocorticoid dosing is achieved at the dose intended at time of randomization

        Exclusion Criteria:

          -  Comorbidities (other than lupus nephritis [LN], example, asthma, chronic obstructive
             pulmonary disease) which have required 3 or more courses of systemic glucocorticoids
             within the previous 12 months

          -  Has other inflammatory diseases that might confound the evaluations of efficacy,
             including but not limited to rheumatoid arthritis (RA), psoriatic arthritis (PsA),
             RA/lupus overlap, psoriasis, Crohn's disease, or active Lyme disease

          -  Received PO (orally) cyclophosphamide within 3 months or intravenous (IV)
             cyclophosphamide within 6 months prior to randomization

          -  History of latent or active granulomatous infection, including histoplasmosis or
             coccidioidomycosis, before screening

          -  History of being human immunodeficiency virus (HIV) antibody-positive, or tests
             positive for HIV at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91722</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Ambulatory Care Brooklyn Heights</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Feinstein Institute for Medical Research</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Research, Inc.</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Organizacion Medica de Investigacion (OMI)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aprillus</name>
      <address>
        <city>Caba</city>
        <zip>1046</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramos Mejia</name>
      <address>
        <city>Caba</city>
        <zip>1221</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico Strusberg SA</name>
      <address>
        <city>Cordoba</city>
        <zip>05000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Reumatologia - Ir Medical Center S.A.</name>
      <address>
        <city>Mendoza</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorios Integrados Rosario</name>
      <address>
        <city>Rosario</city>
        <zip>S2000DEJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Privado de Reumatologia</name>
      <address>
        <city>San Miguel De Tucuman</city>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación y Tratamiento Reumatológico S.C.</name>
      <address>
        <city>Ciudad de Mexico</city>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde</name>
      <address>
        <city>Guadalajara</city>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad Reumatologica las Americas S.C.P.</name>
      <address>
        <city>Merida</city>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán</name>
      <address>
        <city>Mexico city</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio de Reumatologia</name>
      <address>
        <city>Mexico</city>
        <zip>07760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central Dr Ignacio Morones Prieto</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gdanski Uniwersytet Medyczny</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malopolskie Badania Kliniczne Sp. z o.o. Sp. k.</name>
      <address>
        <city>Krakow</city>
        <zip>30-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny nr 1 im. N. Barlickiego</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny we Wrocławiu</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLL Medical Center Revma-Med</name>
      <address>
        <city>Kemerovo</city>
        <zip>650070</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omsk Regional Clinical Hospital</name>
      <address>
        <city>Omsk</city>
        <zip>644111</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orenburg State Medical University</name>
      <address>
        <city>Orenburg</city>
        <zip>460000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Medical Sanitary Part No. 157</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. de Basurto</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Fuenlabrada</name>
      <address>
        <city>Madrid</city>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico Univ. de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phramongkutklao Hospital and Medical College</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiangmai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Songklanagarind hospital</name>
      <address>
        <city>Hat Yai</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal non-commercial enterprise of Kharkiv Regional Council Regional Clinical Hospital</name>
      <address>
        <city>Kharkiv</city>
        <zip>61058</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No. 2</name>
      <address>
        <city>Kryvyi Rih</city>
        <zip>50056</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv Railway Clinical Hospital #2 Of Branch 'Health Center' Of The Company 'Ukrainian Railway'</name>
      <address>
        <city>Kyiv</city>
        <zip>03049</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of SI 'NSC 'The M.D.Strazhesko Institute of Cardiology' of NAMS of Ukraine'</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center 'Consylium Medical'</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution 'Institute of Nephrology of the National Academy of Medical Sciences of Ukraine'</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital'</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise 'Odesa Regional Clinical Hospital' Odesa Regional Council</name>
      <address>
        <city>Odessa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-commercial Enterprise 'Ternopil University Hospital' of Ternopil Regional Council</name>
      <address>
        <city>Ternopil</city>
        <zip>46002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center LTD Health Clinic Department of Cardiology and Rheumatology</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

